Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Orchard Therapeutics plc
Headquarters: London, United Kingdom
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Feb 14, 2025
Management Tracks
Berns becomes chairman, CEO of Neumora
Plus: Robin Kenselaar named chief commercial officer at Orchard, and an update from Bluejay
BioCentury | Oct 3, 2024
Management Tracks
New chairs for Progentos, Curve and Eligo
Plus: Nxera names BMS vet Sugita CMO, Japan president, and updates from Achieve, Every Cure and more
BioCentury | Mar 1, 2024
Product Development
Rare disease spotlight: enzyme replacement therapy for the brain
At least seven companies aim to overcome the challenge of delivering an enzyme across the blood-brain barrier to treat MPS IIIA
BioCentury | Nov 20, 2023
Data Byte
FDA, EMA make similar decisions on cell and gene therapies
EMA has grant more expedited approvals than FDA, but regional differences in available therapies mostly due to where the candidates were submitted
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Sep 19, 2023
Product Development
Sept. 18 Quick Takes: Anthos’ mAb meets Phase II bleeding endpoint
Plus: Priority review for Orchard’s ex vivo gene therapy and more from BioNTech, Broken String and FDA
BioCentury | May 16, 2023
Management Tracks
JLABS vet Calcagno becomes CBO of Vir
Plus: Therini names Frank Lee executive chair and updates from OMass, Sapir, Pan Cancer T, and more
BioCentury | Mar 30, 2023
Discovery & Translation
Crystal Mackall: a cell therapy innovator’s view on decision-making
How the Stanford professor and serial entrepreneur thinks about the academia-industry interface, pediatric programs and triaging innovations
BioCentury | Jan 19, 2023
Politics, Policy & Law
Hopes, Fears for Orphan Drug Act
Passed 40 years ago, it may be time for ODA 2.0
BioCentury | Jan 18, 2023
Management Tracks
AZ’s Marshall becomes CEO of Juvenescence
Plus: Gomez retires as CEO from Siga, and updates from Full-Life, Remix, Sanotize and more
Items per page:
1 - 10 of 65